AstraZeneca stock rose over 2% due to potential direct listing on U.S. exchange

From Nasdaq: 2025-07-01 17:18:00

AstraZeneca’s American Depositary Shares (ADSes) saw active trading as the company considers a direct listing on a U.S. exchange. The ADSes rose over 2% on Tuesday, outperforming the S&P 500. The company’s CEO is reportedly contemplating moving the stock market listing and even the headquarters from the U.K. to the U.S. due to concerns about European competitiveness. AstraZeneca has a significant presence in the U.S. healthcare market, making a shift logical. Investors are advised to consider other stocks for potential growth opportunities. The Motley Fool’s Stock Advisor team has identified 10 top stocks that could provide substantial returns.



Read more at Nasdaq: Why AstraZeneca Stock Topped the Market on Tuesday